Clinical trials: Ankylosing Spondylitis (AS)
Ankylosing Spondylitis (AS), Psoriasis
Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases
The objective of this study is to evaluate the effect of adalimumab on health outcomes in participants with rheumatoid arthritis, ankylosing spondylitis and plaque psoriasis.
- Conditions
- Ankylosing Spondylitis (AS), Psoriasis, Rheumatoid Arthritis (RA)
- Trial name
- ADMIT (NCT03339089)
- Where
- 10 sites in China
- Volunteers
- 224 people
- Sponsor
- AbbVie
Ankylosing Spondylitis, Psoriatic Arthritis
Study Evaluating Epidemiology of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in Australia
The study is a cross sectional, epidemiology study of disease severity for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis in four geographic regions in Australia (Illawarra, Sutherland, Hunter Urban and…
- Conditions
- Ankylosing Spondylitis, Psoriatic Arthritis, Rheumatoid Arthritis
- Trial name
- NCT00751387
- Where
- 4 sites in Australia
- Volunteers
- 559 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Ankylosing Spondylitis
Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS)
The purpose of this study is to determine if Jaktinib is safe and effective in participants with active ankylosing spondylitis.
- Trial name
- NCT05861128
- Testing
- Jaktinib
- Where
- China
- Volunteers
- 207 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Ankylosing Spondylitis
16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis
This study will assess the efficacy and safety of secukinumab in patients with active ankylosing spondylitis who are intolerant to or have had an inadequate response to NSAIDs, DMARDs and / or TNFα inhibitor therapy.
- Trial name
- MEASURE 1 (NCT01358175)
- Testing
- Secukinumab (75 mg), Secukinumab (150 mg)
- Where
- 67 sites in United States, Belgium and 12 more
- Volunteers
- 371 people
- Sponsor
- Novartis Pharmaceuticals
Spondylitis, Ankylosing
Extension in AS: Sustainability of Benefits, Safety and Tolerability
This 3-year extension study aims at making available the treatment with secukinumab in prefilled syringes (PFS) to patients with ankylosing spondylitis who took part in phase III study CAIN457F2305, defined as "core study", as…
- Trial name
- MEASURE 1 ext (NCT01863732)
- Testing
- Secukinumab
- Where
- 56 sites in United States, Belgium and 12 more
- Volunteers
- 274 people
- Sponsor
- Novartis Pharmaceuticals
Ankylosing Spondylitis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis
The purpose of the study is to demonstrate the efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared to placebo in the treatment of subjects with active ankylosing spondylitis (AS).
- Trial name
- BE MOBILE 2 (NCT03928743)
- Testing
- Bimekizumab
- Where
- 83 sites in United States, Belgium and 12 more
- Volunteers
- 332 people
- Sponsor
- UCB Biopharma SRL
Axial Spondyloarthritis, Ankylosing Spondylitis
A Study to Assess the Safety of Subcutaneous Secukinumab for Treatment in Adult Indian Participants With Axial Spondyloarthritis (axSpA), Ankylosing Spondylitis (AS), and Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
The aim of this study is to assess the safety of secukinumab in Indian adult participants with axSpA, AS, and nr-axSpA over a 16-week treatment period.
- Conditions
- Axial Spondyloarthritis, Ankylosing Spondylitis, Non-Radiographic Axial Spondyloarthritis
- Trial name
- NCT07737730
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Ankylosing Spondylitis, Axial Spondyloarthritis
Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)
The primary objective of this study was to assess the proportion of participants in the infliximab plus naproxen arm versus the placebo plus naproxen arm, in a population of participants with moderate-to-severe active axial…
- Trial name
- INFAST (NCT00844805)
- Testing
- Infliximab, Naproxen
- Volunteers
- 158 people
- Sponsor
- Merck Sharp & Dohme LLC
Spondylitis, Ankylosing
Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)
This study will assess the safety and efficacy of ixekizumab (LY2439821) compared to placebo in participants with active AS.
- Trial name
- SPIRIT A1 (NCT01870284)
- Testing
- Ixekizumab, Adalimumab
- Where
- 125 sites in United States, Argentina and 13 more
- Sponsor
- Eli Lilly and Company
Ankylosing Spondylitis
A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS)
This study will evaluate the efficacy and safety of 608 in patients with AS.
- Trial name
- NCT07261644
- Testing
- 608 dose
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Ankylosing Spondylitis (AS)
A Study to Investigate the Clinical REsponses in Ankylosing Spondylitis Patients on Adalimumab Therapy in Taiwan (EAST)
The objectives of this prospective observational study is to explore 1-year clinical response via both Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) after…
- Trial name
- EAST (NCT03505892)
- Where
- Taiwan
- Volunteers
- 28 people
- Sponsor
- AbbVie
Ankylosing Spondylitis
A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis
This is a study to evaluate the efficacy and safety of different doses of bimekizumab in subjects with active Ankylosing Spondylitis (AS).
- Trial name
- BE AGILE (NCT02963506)
- Testing
- Bimekizumab
- Where
- 74 sites in United States, Bulgaria and 8 more
- Volunteers
- 303 people
- Sponsor
- UCB Biopharma S.P.R.L.
Ankylosing Spondylitis
Basic Documentation of Adalimumab (Humira) in Patients With Ankylosing Spondylitis (AS)
The research question explored in this study was whether the effectiveness and safety of adalimumab in participants with ankylosing spondylitis was maintained during long-term therapy in routine clinical practice in Germany.
- Trial name
- NCT01079182
- Volunteers
- 4,681 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA
EValuation of HumIRA® in Patients With Active Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in EASTern European Countries
This is a non-interventional, post-marketing, observational study (PMOS) in which Humira (adalimumab) is prescribed in the usual manner in accordance with the terms of the local marketing authorization with regards to dose…
- Conditions
- Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA, Rheumatoid Arthritis (RA
- Trial name
- EviraEAST (NCT01078402)
- Where
- 163 sites in Croatia, Hungary and 5 more
- Volunteers
- 809 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Ankylosing Spondylitis
Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA
The purpose of this global study was to demonstrate the efficacy, safety, and tolerability of an intravenous (i.v.) regimen of secukinumab compared to placebo in participants with active ankylosing spondylitis (AS) or…
- Trial name
- NCT04156620
- Testing
- Secukinumab
- Where
- 102 sites in United States, Belgium and 16 more
- Volunteers
- 527 people
- Sponsor
- Novartis Pharmaceuticals
AS
Efficacy and Safety of IBI303 in Adult Patients With Active Ankylosing Spondylitis
Study of the efficacy and safety of IBI303 compared with adalimumab in adult patients with ankylosing spondylitis (AS) who have had an inadequate response to or who are intolerant to one or more nonsteroidal anti-inflammatory…
- Trial name
- NCT02893254
- Testing
- IBI303, Adalimumab
- Volunteers
- 438 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Ankylosing Spondylitis
Study Evaluating Etanercept and Sulphasalazine in Ankylosing Spondylitis
The purpose of this study is to compare the efficacy of etanercept and sulphasalazine in the treatment of Ankylosing Spondylitis.
- Trial name
- NCT00247962
- Testing
- etanercept, sulphasalazine (SSZ)
- Where
- 83 sites in Australia, Austria and 16 more
- Volunteers
- 566 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Ankylosing Spondylitis (AS)
A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis
The purpose of this study is to evaluate the safety and efficacy of upadacitinib in participants with active ankylosing spondylitis (AS) who have had an inadequate response to at least 2 non-steroidal anti-inflammatory drugs…
- Trial name
- SELECT-AXIS 1 (NCT03178487)
- Testing
- Upadacitinib
- Where
- 101 sites in United States, Australia and 19 more
- Volunteers
- 187 people
- Sponsor
- AbbVie
Ankylosing Spondylitis
An Extension Study to Demonstrate the Equivalence of Long-Term Efficacy and Safety of CT-P13 in Patients With Ankylosing Spondylitis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 1.1
This open-label, single-arm, multicenter, multiple single-dose intravenous (IV) infusion, efficacy, and safety extension study of the Phase 1 Study CT-P13 1.1 is designed to assess the long-term efficacy and safety of multiple…
- Trial name
- NCT01571206
- Testing
- Infliximab
- Where
- South Korea
- Volunteers
- 174 people
- Sponsor
- Celltrion
Ankylosing Spondylitis
Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.
This is an observational study to evaluate the effectiveness and safety of secukinumab in participants with AS who have never used TNFi, JAKi, or IL-17i drugs before.
- Trial name
- ONSET (NCT06905288)
- Testing
- Secukinumab
- Where
- 3 sites in South Korea
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals